Arcellx Inc (ACLX) - Total Assets
Based on the latest financial reports, Arcellx Inc (ACLX) holds total assets worth $603.99 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Arcellx Inc (ACLX) shareholders funds for net asset value and shareholders' equity analysis.
Arcellx Inc - Total Assets Trend (2018–2025)
This chart illustrates how Arcellx Inc's total assets have evolved over time, based on quarterly financial data.
Arcellx Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Arcellx Inc's total assets of $603.99 Million consist of 76.5% current assets and 23.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.3% |
| Accounts Receivable | $3.60 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Arcellx Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Arcellx Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Arcellx Inc's current assets represent 76.5% of total assets in 2025, a decrease from 92.5% in 2018.
- Cash Position: Cash and equivalents constituted 13.3% of total assets in 2025, down from 91.9% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Arcellx Inc Competitors by Total Assets
Key competitors of Arcellx Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
USA | $319.43 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Arcellx Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.44 | 4.78 | 9.36 |
| Quick Ratio | 4.44 | 4.78 | 9.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $357.98 Million | $473.90 Million | $44.09 Million |
Arcellx Inc - Advanced Valuation Insights
This section examines the relationship between Arcellx Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.73 |
| Latest Market Cap to Assets Ratio | 11.15 |
| Asset Growth Rate (YoY) | -15.1% |
| Total Assets | $603.99 Million |
| Market Capitalization | $6.73 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Arcellx Inc's assets at a significant premium (11.15x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Arcellx Inc's assets decreased by 15.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Arcellx Inc (2018–2025)
The table below shows the annual total assets of Arcellx Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $603.99 Million | -15.09% |
| 2024-12-31 | $711.33 Million | -13.79% |
| 2023-12-31 | $825.13 Million | +162.93% |
| 2022-12-31 | $313.82 Million | +143.68% |
| 2021-12-31 | $128.78 Million | +123.22% |
| 2020-12-31 | $57.69 Million | +32.36% |
| 2019-12-31 | $43.59 Million | +175.66% |
| 2018-12-31 | $15.81 Million | -- |
About Arcellx Inc
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a prod… Read more